Author, as appears in the article.: Marin, Lluis Masana; Gil, Nuria Plana;
Department: Medicina i Cirurgia
URV's Author/s: Masana MarÃn, Luis
Keywords: Targets Low-density lipoprotein cholesterol Inhibitor atp citrate lyase Hyperlipidemia Bempedoic acid Atp-citrate lyase Atherosclerosis Activated protein-kinase
Abstract: Bempedoic acid acts by inhibiting adenosine triphosphate-citrate lyase (ACL) and consequently cholesterol biosynthesis, leading to increased expression of LDL receptors and increasing low-density lipoproteins (LDL-C) plasma clearence. It is a prodrug for oral administration with intracellular activation. It is activatedin liver cells and to a lesser extent in kidney cells, being absent in adipose tissue and muscle cells. Therefore, unlike statins, its potential myotoxic effect is very limited. It has recently been approved as a lipid-lowering drug in combination with diet, with statins, or with other lipid-lowering drugs in patients with hypercholesterolaemia, mixed dyslipidaemia, statin intolerance, or when these are contraindicated. The marketing of bempedoic acid implies, in clinical practice, having a new family of lipid-lowering drugs. (c) 2021 Sociedad Espanola de Arteriosclerosis. Published by Elsevier Espana, S.L.U. All rights reserved.
Thematic Areas: Pharmacology (medical) Peripheral vascular disease Medicina iii Medicina i Cardiology and cardiovascular medicine
licence for use: https://creativecommons.org/licenses/by/3.0/es/
Author's mail: luis.masana@urv.cat
Author identifier: 0000-0002-0789-4954
Record's date: 2024-07-27
Papper version: info:eu-repo/semantics/publishedVersion
Link to the original source: https://www.sciencedirect.com/science/article/pii/S0214916821000462?via%3Dihub
Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
Papper original source: Clinica E Investigacion En Arteriosclerosis. 33 53-57
APA: Marin, Lluis Masana; Gil, Nuria Plana; (2021). Bempedoic acid. Mechanism of action and pharmacokinetic and pharmacodynamic properties. Clinica E Investigacion En Arteriosclerosis, 33(), 53-57. DOI: 10.1016/j.arteri.2021.02.012
Article's DOI: 10.1016/j.arteri.2021.02.012
Entity: Universitat Rovira i Virgili
Journal publication year: 2021
Publication Type: Journal Publications
Repositori URV